✦ LIBER ✦

Risedronate results in rapid and consistent risk reduction of vertebral and nonvertebral fractures

✍ Scribed by Susan Broy; Marjorie Gass; Harris McIlwain

Book ID: 117190689
Publisher: Lippincott Williams and Wilkins
Year: 2002
Tongue: English
Weight: 52 KB
Volume: 99
Category: Article
ISSN: 0029-7844
DOI: 10.1016/s0029-7844(02)01799-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Risedronate prevented new vertebral and

Risedronate prevented new vertebral and nonvertebral fractures in postmenopausal women with osteoporosis: Risedronate prevented new vertebral fractures in postmenopausal women with osteoporosis

✍ George Ioannidis; Alexandra Papaioannou; Jonathan D. Adachi 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 75 KB

Severity of prevalent vertebral fracture

Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial

✍ P.D Delmas; H.K Genant; G.G Crans; J.L Stock; M Wong; E Siris; J.D Adachi 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 846 KB

Relationship Between Changes in BMD and

Relationship Between Changes in BMD and Nonvertebral Fracture Incidence Associated With Risedronate: Reduction in Risk of Nonvertebral Fracture Is Not Related to Change in BMD

✍ Nelson B Watts; Piet Geusens; Ian P Barton; Dieter Felsenberg 📂 Article 📅 2005 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 270 KB

Beneficial effects of denosumab for redu

Beneficial effects of denosumab for reducing risk of vertebral and nonvertebral fractures

✍ Chin Lee 📂 Article 📅 2009 🏛 Current Science Inc. 🌐 English ⚖ 162 KB

Relationship between bone mineral densit

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures

✍ Matthew Austin; Yu-Ching Yang; Eric Vittinghoff; Silvano Adami; Steven Boonen; D 📂 Article 📅 2012 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 96 KB

Dual-energy X-ray absorptiometric bone mineral density (DXA BMD) is a strong predictor of fracture risk in untreated patients. However, previous patient-level studies suggest that BMD changes explain little of the fracture risk reduction observed with osteoporosis treatment. We investigated the rele

Risedronate Shows Consistent Reduction o

Risedronate Shows Consistent Reduction of The Risk of New Vertebral Fractures Over Three Years In Proton Pump Inhibitor (PPI) and H2-Receptor Antagonist (H2RA) Users

✍ Lindsay, Robert; Goldstein, Jay L.; Zhou, Xiaojie; Roux, Christian 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 184 KB